As a matter of fact, according to the latest International Consensus Classification of myeloid neoplasms, TP53-mutated AML should be considered as an independent entity associated with a lower likelihood of response to conventional chemotherapy and poor outcome and should be included in the adverse prognostic risk category28. This evidence concerns the gene TP53 and acute myeloid leukemia.